CD274 and lung carcinoma: In contrast to conventional therapies that directly target cancer cells, anti-PD-1/PD-L1 antibodies reactivate the immune system of patients to eradicate tumors, which induces durable and long-lasting antitumor immunity in patients with different tumor types, including lung cancer [7].